Li et al. excluded the patients who died within 30 days of acute coronary syndrome or received P2Y12 inhibitors before the index event, leading to a smaller sample size and a relatively low atherosclerotic burden (13% of patients with underlying coronary artery disease and 3% with peripheral artery disease) and bleeding tendency (3% with prior bleeding) in their study population compared with ours. This evidence concerns the gene P2RY12 and acute coronary syndrome.